Shares in Oxford Nanopore Technologies surged in early trading on Monday, after the FTSE 250 firm said full-year sales had beaten guidance.
Updating on year-end trading, the business - a specialist in nanopore-based molecular sensing technology - said revenues were set to come in between £223m and £224m.
That represents a 22% increase on 2024, or a 24% jump on a constant currency basis.
Oxford Nanopore had previously steered for an increase of between 20% and 23% on a constant currency basis.
It also flagged "continued progress" during the year on its path to profitability.
As at 0830 the stock had jumped 8% at 151.6p.
Driving the "strong" 2025 performance was a 60% surge in clinical revenues. All segments saw revenue growth, however, including biopharma - up 30% - and applied industrial, which reported a 27% spike in sales.
The business also confirmed it had ended the year with around £302m in cash, cash equivalents and other liquid investments, ahead of expectations, following improved working capital.
Oxford Nanopore said the higher-than-expected cash provided "continued balance sheet strength to support execution of the group strategy".
Oxford Nanopore, which was founded in 2005 as a spin out from the Oxford University, is due to publish results for the year to 31 December on 2 March.